A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer.
For more information please visit: https://clinicaltrials.gov/ct2/show/NCT05565378?term=213824&draw=2&rank=1
Comentarios